CDK1 and hepatocellular carcinoma: Although the development of new targeted drugs and multidrug combinations has improved the battlefield for HCC, only about 5-14 percent of patients with HCC have a five-year survival rate [4, 5], with the development of bioinformatics and high-throughput sequencing technology, inhibitor of apoptosis protein (IAP) family members [6], kinesin family members [6], cytochrome P2C (CYP2C) subfamily members [7], CDK1, PBK, RRM2, and ASPM [8].